{"id":"mt-6548","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SARMs like MT-6548 bind to the androgen receptor with tissue selectivity, promoting anabolic effects in skeletal muscle and bone through differential coactivator recruitment. This selectivity aims to provide the benefits of androgens for muscle wasting and bone health without the unwanted androgenic side effects associated with traditional androgens or testosterone replacement therapy.","oneSentence":"MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:16.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting / sarcopenia"},{"name":"Bone health / osteoporosis"}]},"trialDetails":[{"nctId":"NCT03402386","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-01-03","conditions":"Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease","enrollment":42},{"nctId":"NCT03461146","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-05","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":24},{"nctId":"NCT03329196","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-10-30","conditions":"Anemia; Non-dialysis Dependent Chronic Kidney Disease","enrollment":304},{"nctId":"NCT03439137","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-14","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":323},{"nctId":"NCT03645863","phase":"PHASE3","title":"Effects of Iron Supplements on the Pharmacokinetics of MT-6548","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-08-27","conditions":"Healthy","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["vadadustat","AKB-6548"],"phase":"phase_3","status":"active","brandName":"MT-6548","genericName":"MT-6548","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues. Used for Muscle wasting / sarcopenia, Bone health / osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}